Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne, Carterra Partner on COVID-19 Variant Analysis

NEW YORK ─ Bio-Techne and Carterra said Wednesday that they are collaborating to study more than 40 COVID-19 variants, including the Delta variant and other emerging variants as they are discovered.

Financial and other terms of the collaboration were not disclosed.

Minneapolis-based Bio-Techne has developed SARS-CoV-2 variants to fast-track the development of a scalable assay to measure the risk that new variants may evade the immune system, the firms said.

The collaborators are using a high-throughput analytical platform, LSA, developed by Salt Lake City-based Carterra, to characterize panels of SARS-CoV-2 spike and receptor-binding domain variants in an assay.

LSA combines flow printing microfluidics with high-throughput surface plasmon resonance to enable screening and characterization of antibody or variant libraries, including full kinetic profiles. The platform generates binding data for 384 proteins on one chip and can assay up to 1,152 patient samples in a single unattended run, the firms said.

Using 2 µL of patient serum, Carterra LSA generates insights with more than 120 data points, including a variant profile, ACE-2 blocking potential, and isotyping profiles of immunoglobin response, the firms added.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.